MX2024005950A - Radioligandos escindibles para dirigirse a receptores de la superficie celular y sus usos. - Google Patents
Radioligandos escindibles para dirigirse a receptores de la superficie celular y sus usos.Info
- Publication number
- MX2024005950A MX2024005950A MX2024005950A MX2024005950A MX2024005950A MX 2024005950 A MX2024005950 A MX 2024005950A MX 2024005950 A MX2024005950 A MX 2024005950A MX 2024005950 A MX2024005950 A MX 2024005950A MX 2024005950 A MX2024005950 A MX 2024005950A
- Authority
- MX
- Mexico
- Prior art keywords
- compound
- solvate
- pharmaceutically acceptable
- acceptable salt
- cleavable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/081—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the protein being an albumin, e.g. human serum albumin [HSA], bovine serum albumin [BSA], ovalbumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163283361P | 2021-11-26 | 2021-11-26 | |
| PCT/US2022/050952 WO2023097038A1 (en) | 2021-11-26 | 2022-11-23 | Cleavable radioligands for targeting cell surface receptors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024005950A true MX2024005950A (es) | 2024-08-06 |
Family
ID=86540347
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024005950A MX2024005950A (es) | 2021-11-26 | 2022-11-23 | Radioligandos escindibles para dirigirse a receptores de la superficie celular y sus usos. |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12214059B2 (enExample) |
| EP (1) | EP4436979A4 (enExample) |
| JP (1) | JP2024542592A (enExample) |
| KR (1) | KR20240121775A (enExample) |
| CN (1) | CN118451091A (enExample) |
| CA (1) | CA3238734A1 (enExample) |
| CL (1) | CL2024001560A1 (enExample) |
| MX (1) | MX2024005950A (enExample) |
| WO (1) | WO2023097038A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018204872A2 (en) * | 2017-05-05 | 2018-11-08 | Fusion Pharmaceuticals Inc. | Igf-1r monoclonal antibodies and uses thereof |
| EP4436979A4 (en) | 2021-11-26 | 2026-06-10 | Full Life Tech Uk Limited | Cleftable radioligands for targeting cell surface receptors and their uses |
| WO2024126687A1 (en) * | 2022-12-16 | 2024-06-20 | Silence Therapeutics Gmbh | Nucleic acids conjugated to an albumin binding moiety |
| EP4719486A1 (en) * | 2023-05-31 | 2026-04-08 | Full-Life Technologies UK Limited | Conjugates and uses thereof |
| EP4719498A1 (en) * | 2023-05-31 | 2026-04-08 | Full-Life Technologies UK Limited | Radioligands for targeting cell surface receptors and uses thereof |
| WO2025113628A1 (en) * | 2023-11-30 | 2025-06-05 | Full-Life Technologies Hk Limited | Sstr receptor targeting radio compounds and uses thereof |
| CN118240015B (zh) * | 2024-03-21 | 2025-03-21 | 中国科学院近代物理研究所 | 一种针对脑胶质瘤的靶向多肽及放射性示踪剂 |
| WO2026002208A1 (zh) * | 2024-06-28 | 2026-01-02 | 思路迪生物医药(上海)有限公司 | 前列腺特异性膜抗原小分子抑制剂及其放射性核素配合物的制备及应用 |
| WO2026080432A1 (en) * | 2024-10-07 | 2026-04-16 | Beth Israel Deaconess Medical Center, Inc. | Dimeric p-selectin inhibitors and uses thereof |
| CN121991166A (zh) * | 2024-11-05 | 2026-05-08 | 成都纽瑞特医疗科技股份有限公司 | 放射性配体化合物及其用途 |
| WO2026119233A1 (en) * | 2024-12-04 | 2026-06-11 | Full-Life Technologies Uk Limited | Conjugates and uses thereof |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5021556A (en) | 1987-07-22 | 1991-06-04 | Neorx Corporation | Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides |
| US5075099A (en) | 1988-05-31 | 1991-12-24 | Neorx Corporation | Metal radionuclide chelating compounds for improved chelation kinetics |
| US5364613A (en) | 1989-04-07 | 1994-11-15 | Sieving Paul F | Polychelants containing macrocyclic chelant moieties |
| US5367080A (en) | 1990-11-08 | 1994-11-22 | Sterling Winthrop Inc. | Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods |
| US5886142A (en) | 1997-05-20 | 1999-03-23 | Thomas Jefferson University | Radiolabeled thrombus imaging agents |
| US8575123B2 (en) * | 2008-04-11 | 2013-11-05 | Tekmira Pharmaceuticals Corporation | Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components |
| EP4420730A3 (en) | 2009-03-19 | 2024-11-13 | The Johns Hopkins University | Psma-targeting compounds and uses thereof |
| ES2743482T3 (es) * | 2014-05-06 | 2020-02-19 | Univ Johns Hopkins | Inhibidores de PSMA marcados con metal/radiometal para obtención de imágenes dirigidas a PSMA y radioterapia |
| MX392700B (es) | 2016-08-10 | 2025-03-11 | Cancer Targeted Tech Llc | Inhibidores de antígeno de la membrana específico para la próstata (psma) quelados. |
| KR102724812B1 (ko) * | 2017-04-05 | 2024-11-01 | 코넬 유니버시티 | 영상화 및 항종양 치료요법에 유용한 조정 가능한 약동학을 갖는 삼작용성 작제물 |
| CA3060143A1 (en) * | 2017-05-24 | 2018-11-29 | Itm Isotopen Technologien Munchen Ag | Novel psma-binding agents and uses thereof |
| AU2018352731B2 (en) | 2017-10-22 | 2023-10-05 | Provincial Health Services Authority | Novel radiometal-binding compounds for diagnosis or treatment of prostate specific membrane antigen-expressing cancer |
| WO2019165200A1 (en) | 2018-02-22 | 2019-08-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents for targeting prostate cancer |
| KR102156385B1 (ko) | 2018-03-30 | 2020-09-15 | (주)퓨쳐켐 | 전립선암 진단 및 치료를 위한 psma-표적 방사성의약품 |
| WO2019246311A1 (en) | 2018-06-19 | 2019-12-26 | Lumiphore, Inc. | Macrocycle conjugates |
| ES3038393T3 (en) * | 2018-08-09 | 2025-10-13 | Hoffmann La Roche | Cleavable linker for peptide synthesis |
| US20200078478A1 (en) | 2018-09-10 | 2020-03-12 | Ming-Hsin Li | Structural molecule of peptide derivative for PSMA-targeting radiotherapy diagnosis and treatment |
| KR20210116437A (ko) | 2018-11-20 | 2021-09-27 | 코넬 유니버시티 | 방사성핵종의 마크로사이클릭 복합체 및 암의 방사선 요법에서의 이의 용도 |
| WO2021046233A1 (en) | 2019-09-03 | 2021-03-11 | Cancer Targeted Technology Llc | Chelate-containing psma inhibitors |
| WO2021163498A1 (en) | 2020-02-14 | 2021-08-19 | Northwestern University | Retrograde neuronal tracers detectable by fluorescence and other imaging methods |
| TWI908773B (zh) * | 2020-03-04 | 2025-12-21 | 日商日本醫事物理股份有限公司 | 化合物及放射性標誌化合物 |
| JP7894086B2 (ja) | 2020-05-06 | 2026-07-23 | コーネル ユニヴァーシティー | 銅含有セラグノスティック化合物及びその使用の方法 |
| EP4436979A4 (en) | 2021-11-26 | 2026-06-10 | Full Life Tech Uk Limited | Cleftable radioligands for targeting cell surface receptors and their uses |
-
2022
- 2022-11-23 EP EP22899414.1A patent/EP4436979A4/en active Pending
- 2022-11-23 MX MX2024005950A patent/MX2024005950A/es unknown
- 2022-11-23 JP JP2024531425A patent/JP2024542592A/ja active Pending
- 2022-11-23 CN CN202280078538.7A patent/CN118451091A/zh active Pending
- 2022-11-23 CA CA3238734A patent/CA3238734A1/en active Pending
- 2022-11-23 WO PCT/US2022/050952 patent/WO2023097038A1/en not_active Ceased
- 2022-11-23 KR KR1020247021297A patent/KR20240121775A/ko active Pending
-
2024
- 2024-03-13 US US18/604,400 patent/US12214059B2/en active Active
- 2024-05-23 CL CL2024001560A patent/CL2024001560A1/es unknown
- 2024-12-03 US US18/967,265 patent/US12673122B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CL2024001560A1 (es) | 2025-03-28 |
| CN118451091A (zh) | 2024-08-06 |
| US12214059B2 (en) | 2025-02-04 |
| EP4436979A1 (en) | 2024-10-02 |
| AU2022397307A1 (en) | 2024-06-06 |
| US20240382630A1 (en) | 2024-11-21 |
| JP2024542592A (ja) | 2024-11-15 |
| EP4436979A4 (en) | 2026-06-10 |
| KR20240121775A (ko) | 2024-08-09 |
| WO2023097038A1 (en) | 2023-06-01 |
| US20250099632A1 (en) | 2025-03-27 |
| US12673122B2 (en) | 2026-07-07 |
| CA3238734A1 (en) | 2023-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2024001560A1 (es) | Radioligandos escindibles para dirigirse a receptores de la superficie celular y usos de los mismos. | |
| MX2021015221A (es) | Compuestos de aminobenzazepina, inmunoconjugados y usos de estos. | |
| MX2021005808A (es) | Complejos macrociclicos de radionucleidos alfa-emisores y su uso en radioterapia focalizada de cancer. | |
| MX2025014493A (es) | Compuestos inhibidores de parp1 | |
| JP2015517482A5 (enExample) | ||
| NZ580226A (en) | Dimer compounds as inhibitors of iap | |
| MX2022003740A (es) | Inmunoconjugados de aminobenzazepina unidos a amida y usos de estos. | |
| MX2022003018A (es) | Danavorexton (tak-925) para usarse en el tratamiento de la narcolepsia. | |
| DE60140219D1 (de) | Radiopharmazeutische formulierungen | |
| PH12021552482A1 (en) | Compounds targeting prmt5 | |
| MX2019008207A (es) | Métodos para tratar el cáncer con anticuerpos anti-pd-1. | |
| MX2024009858A (es) | Compuestos y radioligandos para direccion al receptor de neurotensina y usos de los mismos | |
| MX2010006421A (es) | Compuestos organicos. | |
| AR063869A1 (es) | Metodo de radiosensibilizacion de tumores usando un agente radiosensibilizante | |
| EA200801066A1 (ru) | Сельскохозяйственная композиция | |
| MX2009011601A (es) | Agentes terapeuticos utiles para tratar el dolor. | |
| MX2022005821A (es) | Terapia del carcinoma de celulas renales (rcc) usando linfocitos t modificados por ingenieria genetica dirigidos a cd70. | |
| EA201001196A1 (ru) | Соединения 4-пиридинона и их применение для лечения рака | |
| MX2025012347A (es) | Compuestos heterociclicos y usos de estos | |
| CR20240014A (es) | Pirimidinil-pirazoles sustituidos como inhibidores de cdk2 | |
| ES446388A1 (es) | Procedimiento para preparar n-halo sustituido-2-pirrolido- nas. | |
| MX2023013715A (es) | Regímenes de dosis de ecubectedina. | |
| GB573929A (en) | Prevention and destruction of weeds | |
| CR20240016A (es) | Compuestos terapéuticos y procedimientos | |
| JOP20220124A1 (ar) | مشتقات 1، 2، 4-أوكساديازول كناهضات مستقبلات الكبد x |